Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2004;109:2273-2278
Published online before print May 3, 2004, doi: 10.1161/01.CIR.0000129767.45513.71
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
109/19/2273    most recent
01.CIR.0000129767.45513.71v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moussa, I.
Right arrow Articles by Moses, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moussa, I.
Right arrow Articles by Moses, J. W.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Diabetes Complications
Related Collections
Right arrow Restenosis
Right arrow Type 1 diabetes
Right arrow Type 2 diabetes
Right arrow Catheter-based coronary interventions: stents

(Circulation. 2004;109:2273-2278.)
© 2004 American Heart Association, Inc.


Clinical Investigation and Reports

Impact of Sirolimus-Eluting Stents on Outcome in Diabetic Patients

A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) Substudy

Issam Moussa, MD; Martin B. Leon, MD; Donald S. Baim, MD; William W. O’Neill, MD; Jeffery J. Popma, MD; Maurice Buchbinder, MD; Jay Midwall, MD; Charles A. Simonton, MD; Emily Keim, MS; Patrick Wang, MPH; Richard E. Kuntz, MD; Jeffrey W. Moses, MD

From The Lenox Hill Heart and Vascular Institute and Cardiovascular Research Foundation, New York, NY (I.D.M., M.B.L., J.W.M.); Brigham and Women’s Hospital, Boston, Mass (D.S.B., J.J.P., R.E.K.); William Beaumont Hospital, Royal Oak, Mich (W.W.O.); Scripps Memorial Hospital, La Jolla, Calif (M.B.); JFK Memorial Hospital, Palm Beach County. Fla (J.M.); Sanger Clinic, Charlotte, NC (C.A.S.); and Cordis (Johnson & Johnson), Warren, NJ (E.K., P.W.).

Correspondence to Issam Moussa, MD, Lenox Hill Heart and Vascular Institute, 130 East 77th St, 9th Floor, New York, NY 10021. E-mail imoussa{at}lenoxhill.net

Received February 18, 2004; revision received March 23, 2004; accepted March 23, 2004.

Background— Randomized clinical trials have shown that a sirolimus-eluting stent significantly reduces restenosis after percutaneous coronary revascularization. Diabetic patients are known to have a higher risk of restenosis compared with nondiabetic patients. The purpose of this analysis was to determine the impact of sirolimus-eluting stents on outcomes of diabetic compared with nondiabetic patients.

Methods and Results— The SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) trial is a randomized, double-blind study that compared sirolimus-eluting and bare metal stent implantation in 1058 patients with de novo native coronary artery lesions. Diabetes mellitus was present in 279 (26%) patients (diabetes mellitus group, 131 patients received sirolimus-eluting stents and 148 patients received bare metal stents) and was absent in 778 patients (no–diabetes mellitus group, 402 patients received sirolimus-eluting stents and 376 patients received bare metal stents). At 270 days, target lesion revascularization was reduced in diabetic patients from 22.3% with bare metal stents to 6.9% with sirolimus-eluting stents (P<0.001) and in nondiabetic patients from 14.1% to 2.99% (P<0.001), respectively. Major adverse cardiac events were reduced in diabetic patients from 25% with bare metal stents to 9.2% with sirolimus-eluting stents (P<0.001) and from 16.5% to 6.5% (P<0.001) in nondiabetic patients, respectively.

Conclusions— Implantation of sirolimus-eluting stents compared with bare metal stents in de novo coronary lesions reduces major adverse cardiac events in patients with and without diabetes mellitus. However, among patients receiving sirolimus-eluting stents, there remains a trend toward a higher frequency of repeat intervention in diabetic patients compared with nondiabetic patients, particularly in the insulin-requiring patients.


Key Words: stents • diabetes mellitus • restenosis




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. M. Breen, K. K. Chan, J. K. Dhaliwall, M. R. Ward, N. Al Koudsi, L. Lam, M. De Souza, H. Ghanim, P. Dandona, D. J. Stewart, et al.
Insulin Increases Reendothelialization and Inhibits Cell Migration and Neointimal Growth After Arterial Injury
Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 1060 - 1066.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
T. Takagi, H. Okura, Y. Kobayashi, T. Kataoka, H. Taguchi, I. Toda, K. Tamita, A. Yamamuro, Y. Sakanoue, A. Ito, et al.
A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study)
J. Am. Coll. Cardiol. Intv., June 1, 2009; 2(6): 524 - 531.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
L. J. Kim, S. B. King III, K. Kent, M. M. Brooks, K. E. Kip, J. D. Abbott, A. K. Jacobs, C. Rihal, W. A. Hueb, E. Alderman, et al.
Factors Related to the Selection of Surgical Versus Percutaneous Revascularization in Diabetic Patients With Multivessel Coronary Artery Disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) Trial
J. Am. Coll. Cardiol. Intv., May 1, 2009; 2(5): 384 - 392.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. Weisz, M. B. Leon, D. R. Holmes Jr, D. J. Kereiakes, J. J. Popma, P. S. Teirstein, S. A. Cohen, H. Wang, D. E. Cutlip, and J. W. Moses
Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial.
J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1488 - 1497.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Shan, T. B. Nguyen, H. Totary-Jain, H. Dansky, S. O. Marx, and A. R. Marks
Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors
PNAS, December 2, 2008; 105(48): 19006 - 19011.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Garg, S.-L. T. Normand, T. S. Silbaugh, R. E. Wolf, K. Zelevinsky, A. Lovett, M. R. Varma, Z. Zhou, and L. Mauri
Drug-Eluting or Bare-Metal Stenting in Patients With Diabetes Mellitus: Results From the Massachusetts Data Analysis Center Registry
Circulation, November 25, 2008; 118(22): 2277 - 2285.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
L. O. Jensen, M. Maeng, P. Thayssen, E. H. Christiansen, K. N. Hansen, A. Galloe, H. Kelbaek, J. F. Lassen, and L. Thuesen
Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: The Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial
Eur. Heart J., November 2, 2008; 29(22): 2733 - 2741.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
C. Stettler, S. Allemann, S. Wandel, A. Kastrati, M. C. Morice, A. Schomig, M. E Pfisterer, G. W Stone, M. B Leon, J. S. d. Lezo, et al.
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis
BMJ, August 29, 2008; 337(aug29_3): a1331 - a1331.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. S. Brar, J. Kim, S. K. Brar, R. Zadegan, M. Ree, I.-L. A. Liu, P. Mansukhani, V. Aharonian, R. Hyett, and A. Y.-J. Shen
Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions.
J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2220 - 2227.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Ortolani, M. Balducelli, P. Marzaroli, G. Piovaccari, A. Menozzi, V. Guiducci, P. Sangiorgio, F. Tarantino, G. Geraci, F. Castriota, et al.
Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions: Results From a Real-World Multicenter Registry
Circulation, February 19, 2008; 117(7): 923 - 930.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
W. E. Hellings, F. L. Moll, J.-P. P. M. De Vries, R. G. A. Ackerstaff, K. A. Seldenrijk, R. Met, E. Velema, W. J. M. Derksen, D. P. V. De Kleijn, and G. Pasterkamp
Atherosclerotic Plaque Composition and Occurrence of Restenosis After Carotid Endarterectomy
JAMA, February 6, 2008; 299(5): 547 - 554.
[Abstract] [Full Text] [PDF]


Home page
Ther Adv Cardiovasc DisHome page
F. Saia, A. Marzocchi, and A. Branzi
Review: The safety of drug-eluting stents
Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 43 - 52.
[Abstract] [PDF]


Home page
Card Surg AdultHome page
J. M. Wilson and J. T. Willerson
Myocardial Revascularization with Percutaneous Devices
Card. Surg. Adult, January 1, 2008; 3(2008): 573 - 598.
[Full Text]


Home page
J Am Coll Cardiol IntvHome page
S. R. Mulukutla, H. A. Vlachos, O. C. Marroquin, F. Selzer, E. M. Holper, J. D. Abbott, W. K. Laskey, D. O. Williams, C. Smith, W. D. Anderson, et al.
Impact of Drug-Eluting Stents Among Insulin-Treated Diabetic Patients A Report from the NHLBI Dynamic Registry.
J. Am. Coll. Cardiol. Intv., January 1, 2008; 1: 139 - 147.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
J. DiChiara, K. P. Bliden, U. S. Tantry, M. S. Hamed, M. J. Antonino, T. A. Suarez, O. Bailon, A. Singla, and P. A. Gurbel
The Effect of Aspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients: An Analysis From the Aspirin-Induced Platelet Effect (ASPECT) Study
Diabetes, December 1, 2007; 56(12): 3014 - 3019.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. Baumgart, V. Klauss, F. Baer, F. Hartmann, H. Drexler, W. Motz, H. Klues, S. Hofmann, W. Volker, T. Pfannebecker, et al.
One-Year Results of the SCORPIUS Study: A German Multicenter Investigation on the Effectiveness of Sirolimus-Eluting Stents in Diabetic Patients
J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1627 - 1634.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Togni, S. Eber, J. Widmer, M. Billinger, P. Wenaweser, S. Cook, R. Vogel, C. Seiler, F. R. Eberli, W. Maier, et al.
Impact of Vessel Size on Outcome After Implantation of Sirolimus-Eluting and Paclitaxel-Eluting Stents: A Subgroup Analysis of the SIRTAX Trial
J. Am. Coll. Cardiol., September 18, 2007; 50(12): 1123 - 1131.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Daemen and P. W. Serruys
Drug-Eluting Stent Update 2007: Part II: Unsettled Issues
Circulation, August 21, 2007; 116(8): 961 - 968.
[Full Text] [PDF]


Home page
Eur Heart JHome page
P. Jimenez-Quevedo, M. Sabate, D. J. Angiolillo, F. Alfonso, R. Hernandez-Antolin, M. SanMartin, J. A. Gomez-Hospital, C. Banuelos, J. Escaned, R. Moreno, et al.
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial
Eur. Heart J., August 2, 2007; 28(16): 1946 - 1952.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Marzocchi, F. Saia, G. Piovaccari, A. Manari, E. Aurier, A. Benassi, A. Cremonesi, G. Percoco, E. Varani, P. Magnavacchi, et al.
Long-Term Safety and Efficacy of Drug-Eluting Stents: Two-Year Results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) Multicenter Registry
Circulation, June 26, 2007; 115(25): 3181 - 3188.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. E. Cutlip, S. Windecker, R. Mehran, A. Boam, D. J. Cohen, G.-A. van Es, P. Gabriel Steg, M.-a. Morel, L. Mauri, P. Vranckx, et al.
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Circulation, May 1, 2007; 115(17): 2344 - 2351.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. S. Fox, S. Coady, P. D. Sorlie, R. B. D'Agostino Sr, M. J. Pencina, R. S. Vasan, J. B. Meigs, D. Levy, and P. J. Savage
Increasing Cardiovascular Disease Burden Due to Diabetes Mellitus: The Framingham Heart Study
Circulation, March 27, 2007; 115(12): 1544 - 1550.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. Berry, J.-C. Tardif, and M. G. Bourassa
Coronary Heart Disease in Patients With Diabetes: Part II: Recent Advances in Coronary Revascularization
J. Am. Coll. Cardiol., February 13, 2007; 49(6): 643 - 656.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
Y. Ben-Gal, Y. Moshkovitz, N. Nesher, G. Uretzky, R. Braunstein, A. Hendler, E. Zivi, I. Herz, and R. Mohr
Drug-Eluting Stents Versus Coronary Artery Bypass Grafting in Patients with Diabetes Mellitus
Ann. Thorac. Surg., November 1, 2006; 82(5): 1692 - 1697.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S.-F. Yan, E. Harja, M. Andrassy, T. Fujita, and A. M. Schmidt
Protein Kinase C {beta}/Early Growth Response-1 Pathway: A Key Player in Ischemia, Atherosclerosis, and Restenosis
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A47 - A55.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. J. Suttorp, G. J. Laarman, B. M. Rahel, J. C. Kelder, M. A.R. Bosschaert, F. Kiemeneij, J. M. ten Berg, E. T. Bal, B. J. Rensing, F. D. Eefting, et al.
Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): A Randomized Comparison of Bare Metal Stent Implantation With Sirolimus-Eluting Stent Implantation for the Treatment of Total Coronary Occlusions
Circulation, August 29, 2006; 114(9): 921 - 928.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
V K Bhatia and C Di Mario
Darwin and the survival of the fittest in modern interventional cardiology
Heart, August 1, 2006; 92(8): 1017 - 1018.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
V. I. Patel, S. Daniel, C. R. Longo, G. V. Shrikhande, S. T. Scali, E. Czismadia, C. M. Groft, T. Shukri, C. Motley-Dore, H. E. Ramsey, et al.
A20, a modulator of smooth muscle cell proliferation and apoptosis, prevents and induces regression of neointimal hyperplasia
FASEB J, July 1, 2006; 20(9): 1418 - 1430.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Jimenez-Quevedo, M. Sabate, D. J. Angiolillo, M. A. Costa, F. Alfonso, J. A. Gomez-Hospital, R. Hernandez-Antolin, C. Banuelos, J. Goicolea, F. Fernandez-Aviles, et al.
Vascular Effects of Sirolimus-Eluting Versus Bare-Metal Stents in Diabetic Patients: Three-Dimensional Ultrasound Results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial
J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2172 - 2179.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Kastrati, A. Dibra, J. Mehilli, S. Mayer, S. Pinieck, J. Pache, J. Dirschinger, and A. Schomig
Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting Stents
Circulation, May 16, 2006; 113(19): 2293 - 2300.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W. Kim, M. H. Jeong, K. H. Kim, I. S. Sohn, Y. J. Hong, H. W. Park, J. H. Kim, Y. K. Ahn, J. G. Cho, J. C. Park, et al.
The Clinical Results of a Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab: ReoPro)-Coated Stent in Acute Myocardial Infarction
J. Am. Coll. Cardiol., March 7, 2006; 47(5): 933 - 938.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
R. Seabra-Gomes
Percutaneous coronary interventions with drug eluting stents for diabetic patients.
Heart, March 1, 2006; 92(3): 410 - 419.
[Full Text] [PDF]


Home page
CJASNHome page
M. E. Williams
Coronary Revascularization in Diabetic Chronic Kidney Disease/End-Stage Renal Disease: A Nephrologist's Perspective
Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 209 - 220.
[Full Text] [PDF]


Home page
NEJMHome page
J. A. Alarcon, J. M. Arribas, V. Ruiz, L. Czupryniak, M. Pawlowski, J. Loba, R. F. Bonvini, V. Verin, R. Waksman, R. M. Wolfram, et al.
Drug-eluting coronary stents.
N. Engl. J. Med., December 1, 2005; 353(22): 2404 - 2408.
[Full Text] [PDF]


Home page
CirculationHome page
M. Sabate, P. Jimenez-Quevedo, D. J. Angiolillo, J. A. Gomez-Hospital, F. Alfonso, R. Hernandez-Antolin, J. Goicolea, C. Banuelos, J. Escaned, R. Moreno, et al.
Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial
Circulation, October 4, 2005; 112(14): 2175 - 2183.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. B. King III, G. Dangas, J. W. Moses, S. B. King III, G. Dangas, and J. W. Moses
Surgery Is Preferred for the Diabetic With Multivessel Disease
Circulation, September 6, 2005; 112(10): 1500 - 1515.
[Full Text] [PDF]


Home page
NEJMHome page
A. Dibra, A. Kastrati, J. Mehilli, J. Pache, H. Schuhlen, N. von Beckerath, K. Ulm, R. Wessely, J. Dirschinger, A. Schomig, et al.
Paclitaxel-Eluting or Sirolimus-Eluting Stents to Prevent Restenosis in Diabetic Patients
N. Engl. J. Med., August 18, 2005; 353(7): 663 - 670.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. Molnar, S. Yu, N. Mzhavia, C. Pau, I. Chereshnev, and H. M. Dansky
Diabetes Induces Endothelial Dysfunction but Does Not Increase Neointimal Formation in High-Fat Diet Fed C57BL/6J Mice
Circ. Res., June 10, 2005; 96(11): 1178 - 1184.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. J. Kereiakes, R. E. Kuntz, L. Mauri, and M. W. Krucoff
Surrogates, substudies, and real clinical end points in trials of drug-eluting stents
J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1206 - 1212.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W. W. O'Neill, S. R. Dixon, and C. L. Grines
The year in interventional cardiology
J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1117 - 1134.
[Full Text] [PDF]


Home page
Eur Heart JHome page
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al.
Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
Eur. Heart J., April 2, 2005; 26(8): 804 - 847.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. Wessely, J. Hausleiter, C. Michaelis, B. Jaschke, M. Vogeser, S. Milz, B. Behnisch, T. Schratzenstaller, M. Renke-Gluszko, M. Stover, et al.
Inhibition of Neointima Formation by a Novel Drug-Eluting Stent System That Allows for Dose-Adjustable, Multiple, and On-Site Stent Coating
Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 748 - 753.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
J. D. Flaherty and C. J. Davidson
Diabetes and Coronary Revascularization
JAMA, March 23, 2005; 293(12): 1501 - 1508.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. V. Finn, I. F. Palacios, A. Kastrati, and H. K. Gold
Drug-eluting stents for diabetes mellitus: A rush to judgment?
J. Am. Coll. Cardiol., February 15, 2005; 45(4): 479 - 483.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
Y.-m. Yang and I. Moussa
Percutaneous coronary intervention and drug-eluting stents
Can. Med. Assoc. J., February 1, 2005; 172(3): 323 - 325.
[Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
J Butany and M J Collins
Analysis of prosthetic cardiac devices: a guide for the practising pathologist
J. Clin. Pathol., February 1, 2005; 58(2): 113 - 124.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. Mauri, E. J. Orav, A. J. O'Malley, J. W. Moses, M. B. Leon, D. R. Holmes Jr, P. S. Teirstein, J. Schofer, G. Breithardt, D. E. Cutlip, et al.
Relationship of Late Loss in Lumen Diameter to Coronary Restenosis in Sirolimus-Eluting Stents
Circulation, January 25, 2005; 111(3): 321 - 327.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A. J. Scheen, F. Warzee, and V. M.G. Legrand
Drug-eluting stents: meta-analysis in diabetic patients
Eur. Heart J., December 1, 2004; 25(23): 2167 - 2168.
[Full Text] [PDF]


Home page
Eur Heart JHome page
A. Bagust, A. Bakhai, R. Dickson, Y. Dundar, R. A Hill, and T. Walley
Exploring groups at high risk of restenosis
Eur. Heart J., December 1, 2004; 25(23): 2168 - 2169.
[Full Text] [PDF]


Home page
Evid. Based Med.Home page
Other articles noted
Evid. Based Med., September 1, 2004; 9(5): e5 - e5.
[Full Text] [PDF]